Trial reportPLoS pathogens2012
Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.
Trial report in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage.Mucosal immunology · 2017Trial
- Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.Mucosal immunology · 2016Trial
- Trial
- Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.Vaccine · 2014Trial
- Biofilm formation during pneumococcal carriage imprints naturally acquired humoral immunity.PLoS pathogens · 2026Article
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Immune pathways that regulate neutrophil activation and replenishment prevent persistent pneumococcal colonization.PLoS pathogens · 2026Article
- Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.The Lancet. Microbe · 2026Review
- Immune pathways that regulate neutrophil activation and replenishment prevent persistent pneumococcal colonization.bioRxiv : the preprint server for biology · 2026Article
- Biofilm formation during pneumococcal carriage imprints naturally acquired humoral immunity.bioRxiv : the preprint server for biology · 2025Article
- The metabolic, microbial and immunological demands of pneumococcal colonisation.PLoS pathogens · 2025Review
- Obesity, leptin and host defence ofEuropean respiratory review : an official journal of the European Respiratory Society · 2022Review
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Article
- Ethical considerations regarding animal experimentation.Journal of preventive medicine and hygiene · 2022Review
- Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.The Journal of infectious diseases · 2022Article
- Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.Vaccines · 2021Review
- Protective Effect of Nasal Colonisation withVaccines · 2021Article
- The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans.Frontiers in physiology · 2021Review
- Exploring metal availability in the natural niche ofVirulence · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Infectious challenge of the human nasal mucosa elicits immune responses that determine the fate of the host-bacterial interaction; leading either to clearance, colonisation and/or disease. Persistent antigenic exposure from pneumococcal colonisation can induce both humoral and cellular defences that are protective against carriage and disease. We challenged healthy adults intra-nasally with live 23F or 6B Streptococcus pneumoniae in two sequential cohorts and collected nasal wash, bronchoalveolar lavage (BAL) and blood before and 6 weeks after challenge. We hypothesised that both cohorts would successfully become colonised but this did not occur except for one volunteer. The effect of bacterial challenge without colonisation in healthy adults has not been previously assessed. We measured the antigen-specific humoral and cellular immune responses in challenged but not colonised volunteers by ELISA and Flow Cytometry. Antigen-specific responses were seen in each compartment both before and after bacterial challenge for both cohorts. Antigen-specific IgG and IgA levels were significantly elevated in nasal wash 6 weeks after challenge compared to baseline. Immunoglobulin responses to pneumococci were directed towards various protein targets but not capsular polysaccharide. 23F but not 6B challenge elevated IgG anti-PspA in BAL. Serum immunoglobulins did not increase in response to challenge. In neither challenge cohort was there any alteration in the frequencies of TNF, IL-17 or IFNγ producing CD4 T cells before or after challenge in BAL or blood. We show that simple, low dose mucosal exposure with pneumococci may immunise mucosal surfaces by augmenting anti-protein immunoglobulin responses; but not capsular or cellular responses. We hypothesise that mucosal exposure alone may not replicate the systemic immunising effect of experimental or natural carriage in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.